Friday, March 9, 2018

HCV Tx-as-Prevention Strategy Seems to Work in HIV+ MSM

Meeting Coverage MedPage Today > CROI

HCV Tx-as-Prevention Strategy Seems to Work in HIV+ MSM
by Molly Walker, Staff Writer, MedPage Today March 09, 2018
BOSTON -- Two trials successfully examined a "treatment as prevention" strategy for hepatitis C in mostly HIV-infected men who have sex with men (MSM), and were reported by researchers here. 
The first trial found that for hepatitis C virus (HCV)-infected MSM, a shorter 8-week course of grazoprevir/elbasvir, a direct-acting antiviral combination therapy for acute HCV infection was comparable to a 12-week treatment...

Meeting Coverage Across The Web:
Review key presentations presented at CROI
News, slidesets, interviews, and webinars

No comments:

Post a Comment